PinPoint Get PinPoint on the App Store

Cellular research / Compound guide

SS-31 guide

SS-31, or elamipretide, is a cardiolipin-binding peptide studied in mitochondrial disease, including Barth syndrome.[2] The library records FDA accelerated approval for a rare mitochondrial disease indication and separates that status from broader tracking use.[1]

PINPOINT EDITORIAL · UPDATED 05 OCT 2026
FDA-labeled presentation · 3.16 h model input

Editorial still life for cellular research research guides

ILLUSTRATION / COMPOUND LIBRARY SERIES

At a glance

SS-31 library factsCellular research. Routes: subcutaneous. Half-life model input: 3.16 hours. Package: 10 mg / package. FDA-labeled presentation. CATEGORYROUTES IN LIBRARYHALF-LIFE MODEL INPUTTYPICAL PACKAGERESEARCH STATUS Cellular researchsubcutaneous3.16 hours10 mg / packageFDA-labeled presentation SOURCE / PINPOINT COMPOUND LIBRARY

Read the record in context

SS-31's card preserves the library's regulatory context and historical 10 mg supplier package. That catalog amount is currently unverified. The half-life comes from an FDA review, not the label itself, while the separately labeled solution example below has a different package amount and presentation.[1]

What the research says

The elamipretide label describes subcutaneous pharmacokinetics, including approximately 92% bioavailability and peak concentrations within 0.5 to one hour. Investigators also examined renal function because the peptide and its metabolites are excreted in urine. Exposure increased as renal clearance declined in the studied groups.[2][1]

The FDA review supplies the half-life evidence separately: a study in 32 healthy volunteers reported 3.16 hours after subcutaneous administration, while a smaller repeated-exposure study reported 2.8 hours. The library uses the former value, preserving the different populations and designs rather than averaging them together.[3][1]

The label's controlled study in twelve participants with Barth syndrome measured walking distance and fatigue as primary endpoints; superiority over placebo was not demonstrated on those endpoints. Muscle-strength observations came from a longer extension. This specific evidence context does not establish broader claims about mitochondrial or athletic performance.[2]

Cited amounts

The Forzinity label lists elamipretide solution as 280 mg in 3.5 mL, or 80 mg/mL. This separately labeled presentation supplies the primary conversion example. The FDA review also reports a 40 mg subcutaneous study in 32 healthy volunteers; a study amount is not a general administration instruction.[7][1][3]

Open the calculator for amount conversions

Half-life and timing

The 3.16-hour input yields 6.32 hours for two halvings and 15.8 hours for five. The final model fraction is 3.125%. This arithmetic uses the single-amount healthy-volunteer context recorded by the library. Its separate steady-state reference is 2.8 hours, which would produce a 14-hour fifth endpoint if used instead. Different research settings therefore produce different model scales. The guide does not treat either as a personal clearance deadline or silently combine the two datasets into one measured curve.[1][6]

SS-31: modeled fraction over five half-livesStarting at 100 percent, the model halves each 3.16 hours. After 15.8 hours, 3.125 percent remains. This is arithmetic, not a measured concentration. ELAPSED HOURS / MODELED STARTING AMOUNT 0 h100%3.16 h50%6.32 h25%9.48 h12.5%12.64 h6.25%15.8 h3.125% Continue to the calculator

Reconstitution

The primary example uses the prepared Forzinity solution: 280 mg divided by its supplied 3.5 mL equals 80 mg/mL. No additional liquid is assumed. This concentration check preserves the approved presentation and does not select a dose, syringe volume, or broader indication. The inaccessible supplier listing remains an unverified library locator in the sources; its research-vial amount is displayed only in the At a glance snapshot.[7]

280 mg ÷ 3.5 mL = 80 mg/mL
Open SS-31 conversion math

Tracking it in PinPoint

From a reference to a record

Built for peptide, TRT, and GLP-1 schedules. Set up your vial in seconds, log every dose, and see your modeled levels between doses. Enter vial size in mg, mcg, or IU and water volume for instant concentration and syringe units. Track vials and prefilled pens side by side.[5]

The Home curve models your levels between doses from published half-life data. Drag to scrub modeled values at any timestamp, or preview 30 days of a dose pattern. Ask PinPoint provides educational reference with sources; it never recommends a dose or a schedule change. These features record and visualize entered information, with the limits of each compound's source data still applying.

Get PinPoint on the App Store

Frequently asked questions

What does an SS-31 peptide dosage search need to distinguish?
The FDA review reports a research amount in healthy volunteers, while the Forzinity label describes a prepared solution for a specific rare-disease indication. The unverified supplier package is retained only in the library snapshot. These sources do not establish a general longevity plan.[1][7][3]
Where does the SS-31 3.16-hour figure come from?
The library identifies Table 6 of an FDA integrated review and its single-amount healthy-volunteer context. It explicitly says the prescribing label does not state an elimination half-life. The guide therefore cites the review for that number rather than attributing it to the label.[1][6]
Why distinguish the SS-31 study amount from the labeled solution?
The healthy-volunteer study reports an amount administered under its research design. The Forzinity label separately describes the contents and concentration of a prepared solution. Neither quantity validates the unavailable research-catalog package, and a package total does not select an administration amount.[7][3][1]
Can a peptide tracker app record SS-31?
PinPoint's compound library includes SS-31. The app description covers logging compound, dose, site, and pain level, as well as viewing modeled levels between recorded doses. The curve uses published reference inputs and does not account for individual variation. The tracker records the schedule entered by its user; it does not choose a dose or recommend a schedule change.[1][5]

Sources

Facts and reference links were retrieved from the PinPoint application library on 5 October 2026. Links below preserve the library's citations; a catalog source supports a package amount only. Source references carried from the library have not all been independently reverified. Arithmetic examples are identified separately from clinical evidence.

  1. PinPoint compound library, SS-31Snapshot of the application library; its references and uncertainty are retained below.Retrieved 2026-10-05 · library
  2. DailyMed prescribing informationIdentity and research summary checked against this document on 5 October 2026. Clinical pharmacology and product-description sections.Retrieved 2026-10-05 · library-reference
  3. FDA integrated reviewIdentity and research summary checked against this document on 5 October 2026. Abstract and relevant methods/results or product-monograph sections.Retrieved 2026-10-05 · library-reference
  4. Supplier catalog package referenceUnverified package locator: the live product link returns 404. The amount is retained only as a library snapshot in At a glance; it is not an externally verified package input.Retrieved 2026-10-05 · unverified-supplier
  5. PinPoint App Store descriptionFeature wording from the approved application description, not pricing.Retrieved 2026-10-05 · app-description
  6. Unit conversion and exponential-decay arithmeticC = amount / volume; remaining fraction = 2^(-elapsed / half-life). These are illustrations, not measurements.Retrieved 2026-10-05 · arithmetic
  7. Approved product label: package presentationVerified 5 October 2026. Separately labeled presentation; does not validate a research-catalog vial.Retrieved 2026-10-05 · product-label